Search for: "Cambridge Antibody Technology"
Nabriva Therapeutics Appoints Dr David Chiswell as Chief Executive Officer
HSMN NewsFeed,
27 Mar 2009:
Biopharmaceuticals, Personnel
[Nabriva Therapeutics]
|
4-Antibody Appoints Dr. Richard Mason as New Chief Executive Officer
HSMN NewsFeed,
26 Sep 2008:
Biopharmaceuticals, Personnel
[4-Antibody]
|
Royalty Pharma Announces that James Reddoch, Ph.D., Joins Management Team
HSMN NewsFeed,
8 Jul 2008:
Biopharmaceuticals, Personnel
[Royalty Pharma]
|
MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
HSMN NewsFeed,
6 May 2008:
Biopharmaceuticals, Personnel
[MedImmune]
|
SV Life Sciences Appoints Dr. Hamish Cameron as Venture Partner
HSMN NewsFeed,
8 Jan 2008:
Venture Capital, Personnel
[SV Life Sciences]
|
MedImmune Expands Scientific and Engineering Leadership
HSMN NewsFeed,
20 Dec 2007:
Biopharmaceuticals, Personnel
[MedImmune]
|
AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
HSMN NewsFeed,
29 Oct 2007:
Biopharmaceuticals
[MedImmune, Cambridge Antibody Technology, AstraZeneca]
|
Vegenics Licenses From CoGenesys Antibodies Against VEGF-C for Applications Including Oncology
HSMN NewsFeed,
18 Jun 2007:
Biopharmaceuticals, Licensing
[CoGenesys, Vegenics, VEGF-C]
|
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B(R) Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
HSMN NewsFeed,
14 Jun 2007:
Biopharmaceuticals
[Human Genome Sciences, LymphoStat-B, belimumab, lupus]
|
Human Genome Sciences and GlaxoSmithKline Initiate Second Phase 3 Clinical Trial of LymphoStat-B(R) in Systemic Lupus Erythematosus
HSMN NewsFeed,
30 May 2007:
Biopharmaceuticals
[Human Genome Sciences, LymphoStat-B, belimumab, lupus, GlaxoSmithKline]
|
Astrazeneca to Acquire Medimmune for $58 Per Share in a Fully Recommended, All-Cash Transaction with a Total Enterprise Value of $15.2 Billion
HSMN NewsFeed,
23 Apr 2007:
Biopharmaceuticals, Mergers & Acquisitions
[AstraZeneca, MedImmune]
|
Human Genome Sciences and GlaxoSmithKline Announce Initiation of Phase 3 Clinical Trial of LymphoStat-B(R) in Systemic Lupus Erythematosus
HSMN NewsFeed,
13 Feb 2007:
Biopharmaceuticals
[Human Genome Sciences, GlaxoSmithKline, LymphoStat-B, belimumab]
|
AstraZeneca Licenses Regeneron's VelocImmune(R) Technology for Discovering Human Monoclonal Antibodies
HSMN NewsFeed,
5 Feb 2007:
Biopharmaceuticals, Licensing
[Regeneron Pharmaceuticals, AstraZeneca]
|
Cambridge Antibody Technology Licenses Monoclonal Antibody (CAT-213) for Treatment of Allergy Disorders to iCo Therapeutics
HSMN NewsFeed,
8 Jan 2007:
Biopharmaceuticals, Licensing
[Cambridge Antibody Technology, iCo Therapeutics, CAT-213]
|
Cambridge Antibody Technology Announces Senior Management Promotions
HSMN NewsFeed,
8 Dec 2006:
Biopharmaceuticals, Personnel
[Cambridge Antibody Technology]
|
Human Genome Sciences Announces Positive 76-Week Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus
HSMN NewsFeed,
14 Nov 2006:
Biopharmaceuticals
[Human Genome Sciences, LymphoStat-B, belimumab, systemic lupus erythematosus]
|
Royalty Pharma Announces Agreement Regarding the Purchase of the Rights to a Pre-Existing Royalty Interest in HUMIRA(R) From AstraZeneca and CAT
HSMN NewsFeed,
26 Oct 2006:
Biopharmaceuticals
[Royalty Pharma, Abbott, AstraZeneca, HUMIRA, adalimumab]
|
Human Genome Sciences Announces Positive Special Protocol Assessment From FDA for Phase 3 Clinical Trials of LymphoStat-B(TM) In Systemic Lupus Erythematosus
HSMN NewsFeed,
26 Oct 2006:
Biopharmaceuticals, FDA
[Human Genome Sciences, LymphoStat-B, belimumab, systemic lupus erythematosus]
|
Human Genome Sciences Announces Phase 3 Clinical Development Program for LymphoStat-B(TM) in Systemic Lupus Erythematosus
HSMN NewsFeed,
9 Aug 2006:
Biopharmaceuticals
[Human Genome Sciences, LymphoStat-B, belimumab, systemic lupus erythematosus]
|
Human Genome Sciences Announces Full Presentation of Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus
HSMN NewsFeed,
22 Jun 2006:
Biopharmaceuticals
[Human Genome Sciences, LymphoStat-B, belimumab, systemic lupus erythematosus]
|
CancerVax and Micromet Announce Merger Agreement
HSMN NewsFeed,
9 Jan 2006:
Biopharmaceuticals, Mergers & Acquisitions
[CancerVax, Micromet AG]
|
|
|
Public
Feeds 
Full text >>
